Dr. Chloé James
Dr. Chloé James is associate professor and hospital practitioner in the hematology laboratory of Bordeaux University Hospital, specialized in hematology and homeostasis. Within Inserm U1034, she leads a prestigious Inserm ATIP-AVENIR (/Bettencourt-Schueller) research team. She is co-inventor of the FR 04 11 480 patent. Her research focuses particularly on mechanisms of thrombosis.
Chloé James, MD PhD, born in 1977, is an associate professor and hospital practitioner in hematology and hemostasis at Bordeaux University Hospital, and leads an Inserm ATIP-AVENIR – Bettencourt Schueller Foundation team at Bordeaux University, created in 2011. This team focuses mostly on studying the interaction between blood and endothelial cells. During her training, Chloé James was actively involved in the discovery of the JAK2V617F mutation in myeloproliferative neoplasia, within INSERM unit U1009, and under the supervision of William Vainchenker. She is co-inventor of the FR 04 11 480 patent. She works half-time in the hematology laboratory of Bordeaux University Hospital and half-time in INSERM unit U1034. She runs an outpatient clinic for patients with a myoproliferative syndrome with thrombotic complications and coordinates the implementation of a cell collection from these patients for research purposes. Chloé James also set up a national translational study on biological markers of thrombosis in patients with myeloproliferative disease. Discoveries emerging from these research activities will be used to study the role of thrombosis in cerebral small artery disease using cutting-edge approaches and techniques.
1. Rivière É, Viallard JF, Guy A, Kilani B, Vieira-Dias J, Pons AC, Couffinhal T, Pellegrin JL, James C. Intrinsically impaired platelet production in somepatients with persistent or chronic immune thrombocytopenia. Br J Haematol. 2015;170:408-15.
2. Riviere E, Saint-Léger M, James C, Delmas Y, Clouzeau B, Bui N, Vital A, Coppo P, Gruson D, Boyer A. Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion. 2015; 55:1798-802.
3. Debrincat MA, Josefsson EC, James C, Henley KJ, Ellis S, Lebois M, Betterman KL, Lane RM, Rogers KL, White MJ, Roberts AW, Harvey NL, Metcalf D, Kile BT. Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood. 2012;119:5850-8.
4. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, Nurden P, Mason KD, O'Reilly LA, Roberts AW, Metcalf D, Huang DC, Kile BT. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011; 208:2017-31.
5. Takiguchi M, James C, Josefsson EC, Carmichael CL, Premsrirut PK, Lowe SW, Hamilton JR, Huang DC, Kile BT, Dickins RA. Transgenic, inducible RNAi in megakaryocytes and platelets in mice. J Thromb Haemost. 2010; 8:2751-6.